TransMedics (NSDQ:TMDX) posted fourth-quarter results this week that beat the consensus forecast on Wall Street.
The Andover, Mass.-based company — a maker of transplant organ preservation tech — reported losses of -$6.3 million, or -23¢ per share, on sales of $7.6 million for the three months ended Dec. 31, 2020, for a sales growth of 25% compared with Q4 2019.
Earnings per share were -23¢, 1¢ ahead of The Street, where analysts were looking for sales of $6 million.
“Fourth-quarter sales exceeded expectations and were driven primarily by the recovery of U.S. OCS Lung procedure volumes as well as progress with the OCS DCD Heart and the OCS Liver CAP clinical programs,” president and CEO Waleed Hassanein said in a news release. “We are now focused on leveraging the progress made with our National OCS Program in 2020 and advancing our FDA initiatives in the upcoming months to accelerate our growth through 2021 and beyond.”
TransMedics did not provide a financial outlook for the fiscal year 2021.
Shares in TMDX were up 2.04% to $40.50 apiece in pre-market trading.